Iterum Therapeutics (ITRM) Fundamental Analysis: Revenue, Earnings & Valuation

6.70 / 10

Outperform

Fundamentally, ITRM scores 6.7/10, rated Outperform. Strengths include high accounts‑receivable turnover, robust interest coverage, strong revenue growth and inventory turnover. Weaknesses are negative income‑tax ratio and low fixed‑asset turnover, tempering the positive outlook.

Analysis Checks(8/10)

Revenue-MV

Value-2.72

Score3/3

Weight29.91%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value78.05

Score2/3

Weight1.59%

1M Return0.58%

Inventory turnover ratio

Value0.03

Score3/3

Weight-1.70%

1M Return-0.67%

Accounts receivable turnover ratio

Value1.74

Score2/3

Weight-1.68%

1M Return-0.65%

PB-ROE

Value-0.34

Score2/3

Weight33.54%

1M Return8.98%

Income tax / Total profit (%)

Value-1.25

Score1/3

Weight-1.54%

1M Return-0.59%

Fixed assets turnover ratio

Value19.02

Score1/3

Weight-3.15%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-1.90%

1M Return-0.73%

Cost of sales ratio (%)

Value5.13

Score2/3

Weight-1.86%

1M Return-0.74%

Asset-MV

Value-0.48

Score3/3

Weight46.80%

1M Return13.09%

Is ITRM undervalued or overvalued?

ITRM scores 6.70/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.00% ROE, 0.00% net margin, -0.08 P/E ratio, -0.25 P/B ratio, and 63.82% earnings growth, these metrics solidify its Outperform investment rating.